Swedencare AB (publ) (SECARE.ST)
SEK 48.8
(-2.4%)
SEK 48.8
(-2.4%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.44 Billion SEK | -22.79% |
| 2022 | 1.86 Billion SEK | 165.24% |
| 2021 | 703.71 Million SEK | 406.52% |
| 2020 | 138.93 Million SEK | 6984.75% |
| 2019 | 1.96 Million SEK | 96.1% |
| 2018 | 1 Million SEK | -88.89% |
| 2017 | 9 Million SEK | -47.06% |
| 2016 | 17 Million SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.6 Billion SEK | 11.25% |
| 2024 Q3 | 1.49 Billion SEK | -3.73% |
| 2024 Q2 | 1.36 Billion SEK | -14.71% |
| 2023 Q1 | 1.85 Billion SEK | -0.52% |
| 2023 Q4 | 1.44 Billion SEK | -16.35% |
| 2023 FY | 1.44 Billion SEK | -22.79% |
| 2023 Q3 | 1.72 Billion SEK | -4.77% |
| 2023 Q2 | 1.8 Billion SEK | -2.57% |
| 2022 Q1 | 1.56 Billion SEK | 122.75% |
| 2022 Q3 | 2.71 Billion SEK | 71.61% |
| 2022 FY | 1.86 Billion SEK | 165.24% |
| 2022 Q2 | 1.58 Billion SEK | 0.91% |
| 2022 Q4 | 1.86 Billion SEK | -31.24% |
| 2021 Q4 | 703.71 Million SEK | 13.87% |
| 2021 FY | 703.71 Million SEK | 406.52% |
| 2021 Q3 | 618 Million SEK | 168.7% |
| 2021 Q2 | 230 Million SEK | 111.74% |
| 2021 Q1 | 108.62 Million SEK | -21.81% |
| 2020 Q3 | 34.37 Million SEK | 1867.66% |
| 2020 FY | 138.93 Million SEK | 6984.75% |
| 2020 Q2 | 1.74 Million SEK | -9.29% |
| 2020 Q1 | 1.92 Million SEK | -1.78% |
| 2020 Q4 | 138.93 Million SEK | 304.17% |
| 2019 Q3 | 2.38 Million SEK | -11.95% |
| 2019 Q2 | 2.71 Million SEK | -26.92% |
| 2019 FY | 1.96 Million SEK | 96.1% |
| 2019 Q1 | 3.71 Million SEK | 271.1% |
| 2019 Q4 | 1.96 Million SEK | -17.88% |
| 2018 Q4 | 1 Million SEK | -80.0% |
| 2018 FY | 1 Million SEK | -88.89% |
| 2018 Q3 | 5 Million SEK | -28.57% |
| 2018 Q2 | 7 Million SEK | -22.22% |
| 2018 Q1 | 9 Million SEK | 0.0% |
| 2017 FY | 9 Million SEK | -47.06% |
| 2017 Q2 | 13 Million SEK | -23.53% |
| 2017 Q3 | 13 Million SEK | 0.0% |
| 2017 Q4 | 9 Million SEK | -30.77% |
| 2017 Q1 | 17 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 17 Million SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 FY | 17 Million SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 26.35 Million SEK | -5368.205% |
| Enzymatica AB (publ) | 24.88 Million SEK | -5691.673% |
| Enorama Pharma AB (publ) | 303 Thousand SEK | -475543.564% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | 3.46 Million SEK | -41469.08% |
| Nanexa AB (publ) | 2.08 Million SEK | -68956.061% |
| Newbury Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| ODI Pharma AB | - SEK | -Infinity% |
| Orexo AB (publ) | 448.4 Million SEK | -221.409% |
| Probi AB (publ) | 38.21 Million SEK | -3671.59% |
| Swedish Orphan Biovitrum AB (publ) | 11.35 Billion SEK | 87.309% |
| Toleranzia AB | 850 Thousand SEK | -169452.941% |
| Vivesto AB | 5.18 Million SEK | -27717.024% |